Celanese Presents Advancements in Pharmaceutical Controlled Release at Polymers in Medicine and Biology Conference
Mon, September 14 2015
Celanese materials experts will discuss the challenges of developing and commercializing new innovations while trying to meet ever-changing regulatory requirements. And building upon clinically-approved materials technology, Celanese will discuss how it is helping to find middle ground and expand drug product technology.
“Our pharmaceutical EVA, VitalDose®,
is a proven, controlled-release excipient that has been clinically
approved in drug delivery systems for many years,” said
“Celanese collaborates with many early-stage investigators conducting
the essential research into the improvement of human health using
devices, drug products and systems that address chronic needs in
metabolic disease, cancer, addiction, infection, women’s health, and
combination therapies, among others,” said
Celanese presentation sessions:
-
Jose Reyes will present “Solving the Medical Polymers Paradox with Ethylene Vinyl Acetate Copolymers for Enabling Advanced Delivery of Proteins and Stem Cells” onTuesday, September 15, 2015 at9:00 a.m. -
Don Loveday will lead the Entrepreneurship sessions onWednesday, September 16 , from3:00 p.m. to 5:45 p.m. , featuring presentations from ExThera, Google, Healionics, and Profusa, among others.
For more information about Celanese’s controlled release pharmaceutical EVA, VitalDose®, visit www.vitaldose.com.
About Celanese
All registered trademarks are owned by
Forward-Looking Statements
This release may contain “forward-looking statements,” which include
information concerning the company’s plans, objectives, goals,
strategies, future revenues or performance, capital expenditures,
financing needs and other information that is not historical
information. When used in this release, the words “outlook,” “forecast,”
“estimates,” “expects,” “anticipates,” “projects,” “plans,” “intends,”
“believes,” and variations of such words or similar expressions are
intended to identify forward-looking statements. All forward-looking
statements are based upon current expectations and beliefs and various
assumptions. There can be no assurance that the company will realize
these expectations or that these beliefs will prove correct. There are a
number of risks and uncertainties that could cause actual results to
differ materially from the forward-looking statements contained in this
release. Numerous factors, many of which are beyond the company’s
control, could cause actual results to differ materially from those
expressed as forward-looking statements. These factors include the
inability to obtain regulatory approvals of the transaction and satisfy
conditions on the proposed terms and schedule and the possibility that
the transaction does not close. Other risk factors include those that
are discussed in the company’s filings with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20150914005088/en/
Celanese
Investor Relations
jon.puckett@celanese.com
or
Media
Relations – Global
william.jacobsen@celanese.com
Source: